Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates endogenous erythropoietin production for the treatment of anaemia in chronic kidney disease, offering an oral alternative to injectable ESAs. Simson Pharma's Daprodustat reference standard and impurities support analytical development for this newer-class anaemia therapy.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Daprodustat Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.